Edaravone Dexborneol
Phase 3Small molecule
Edaravone Dexborneol is one of 92 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.
2
Indications
12
Total Trials
5
Active Trials
91
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Aggrastat
MMedicure
Phase 3
Zastaprazan
YYonsei University
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
PPA Intervention
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
SP-8203
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Y-6
BBeijing Tiantan Hospital
Phase 3
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke10 trials
Show 7 more trials
Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT05121883·200 enrolled
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2·NCT04817527·200 enrolled
Cognitive impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Edaravone Dexborneol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSimcere Pharmaceutical Co., Ltd